Tag: Therapeutics
What Does Milk Do for Babies? | Quanta Magazine
IntroductionMilk is more than just a food for babies. Breast milk has evolved to deliver thousands of diverse molecules including growth factors, hormones and...
Breaking News
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French...
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., Apr 1, 2024 - (ACN Newswire) - China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY)...
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222
Next-generation mRNA vaccine design offers the potential of longer shelf life and storage...
Mapping brain circuits reveals potential treatment targets for brain disorders – Physics World
<a href="https://platoblockchain.net/wp-content/uploads/2024/03/mapping-brain-circuits-reveals-potential-treatment-targets-for-brain-disorders-physics-world-3.jpg" data-fancybox data-src="https://platoblockchain.net/wp-content/uploads/2024/03/mapping-brain-circuits-reveals-potential-treatment-targets-for-brain-disorders-physics-world-3.jpg" data-caption="Disease-specific streamlines Deep brain stimulation revealed the fibre bundles associated with symptom improvement in Parkinson’s disease (green), dystonia (yellow), Tourette’s...
Life Sciences Ontario (LSO) & Ontario Bioscience Innovation Organization (OBIO®) Celebrating Women Leaders Across Ontario’s Life Sciences Sector International Women’s Day – March 8th,...
TORONTO–(BUSINESS WIRE)–Today, women make up 50% of university students enrolled in STEM and health programs in Canada.1 Women identifying as visible minorities make up...
Efficiently fine-tune the ESM-2 protein language model with Amazon SageMaker | Amazon Web Services
In this post, we demonstrate how to efficiently fine-tune a state-of-the-art protein language model (pLM) to predict protein subcellular localization using Amazon SageMaker.
...
ORI Capital Raises $260 Million for Second Life Sciences Fund
– Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally
HONG KONG & NATICK, Mass.–(BUSINESS WIRE)–#biotech—ORI...
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth
ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader...
Self-propelling nanobots shrink bladder tumours in mice by 90% – Physics World
<a href="https://platoblockchain.net/wp-content/uploads/2024/02/self-propelling-nanobots-shrink-bladder-tumours-in-mice-by-90-physics-world-2.jpg" data-fancybox data-src="https://platoblockchain.net/wp-content/uploads/2024/02/self-propelling-nanobots-shrink-bladder-tumours-in-mice-by-90-physics-world-2.jpg" data-caption="Targeted treatment Accumulation of nanobots in the tumour visualized by microscopy. (Courtesy: IRB Barcelona)">
Imagine an army of self-propelling, radioisotope-covered particles...
This Week’s Awesome Tech Stories From Around the Web (Through February 10)
Sam Altman Seeks Trillions of Dollars to Reshape Business of Chips and AIKeach Hagey | The Wall Street Journal“The OpenAI chief executive officer is...
Stemson Therapeutics Announces Technological Breakthrough in New Hair Growth
Demonstrates new engineered functional hair follicles in humanized mice
SAN DIEGO–(BUSINESS WIRE)–#Alopecia—Stemson Therapeutics today announced a major technological advance that clears the path for its...
Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy
Part 2 of the Phase 2/3 SIGLEC clinical trial is designed and powered to serve as the first pivotal trial to support approval of...